ClinicalTrials.gov
ClinicalTrials.gov Menu

The Third Survey of Prescription Pattern of Psychotropic Drugs in China

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01668810
Recruitment Status : Unknown
Verified July 2012 by Si Tianmei, Peking University.
Recruitment status was:  Recruiting
First Posted : August 20, 2012
Last Update Posted : August 20, 2012
Sponsor:
Collaborator:
Xian-Janssen Pharmaceutical Ltd.
Information provided by (Responsible Party):
Si Tianmei, Peking University

Brief Summary:
The investigators aimed to examine the psychotropic prescription pattern in China.

Condition or disease
Prescription

Study Type : Observational
Estimated Enrollment : 7000 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder
Study Start Date : July 2012
Estimated Primary Completion Date : September 2012
Estimated Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Group/Cohort
Beijing region
include six hospitals
Guangdong Province
include 3 hospitals
Jiangsu province
include 3 hospitals
Hebei province
include 6 hospitals
Hubei Province
include 7 hospitals
Shanxi province
include 3 hospitals
Jiangxi province
include 3 hospitals
Jilin province
include 6 hospitals
Sichuan province
include 3 hospitals
Shaanxi province
include 3 hospitals




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
schizophrenia, depression and bipolar disorder patients
Criteria

Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged<18or aged>65


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01668810


Contacts
Contact: Yun-Ai Su, Phd. 8610-82801960 suyunai@gmail.com

Locations
China, Beijing
Institute of mental health, Peking University Recruiting
Beijing, Beijing, China, 100191
Contact: Tianmei Si, PhD.    8610-82801960    si.tian-mei@163.com   
Principal Investigator: Tianmei Si, PhD.         
Sponsors and Collaborators
Peking University
Xian-Janssen Pharmaceutical Ltd.
Investigators
Study Chair: Xin Yu, MD. Peking University

Responsible Party: Si Tianmei, Professor, Peking University
ClinicalTrials.gov Identifier: NCT01668810     History of Changes
Other Study ID Numbers: RISSCH4255
First Posted: August 20, 2012    Key Record Dates
Last Update Posted: August 20, 2012
Last Verified: July 2012

Keywords provided by Si Tianmei, Peking University:
prescription
schizophrenia
depression
bipolar disorder

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Psychotropic Drugs